Diabetic foot ulcers are a major clinical challenge with enormous socioeconomic consequence. All advances in the understanding and management of this problem are eagerly received by wound specialists. The development of bioengineered skin—living skin equivalent—is an interesting event that could be significant in the management of lower extremity wounds such as the diabetic foot ulcer.
Pham HT, Rich J, Veves A.Wound healing in diabetic foot ulceration. A review and commentary. Wounds2000;12(4):79-82.
8.
Margolis DJ, Kantor J, Berlin JA.Healing of diabetic neuropathic foot ulcers receiving standard treatment: a meta-analysis. Diabetes Care1999;22(5):692-695.
9.
Reiber GE, Boyko EJ, Smith DG.Lower extremity foot ulcers and amputations in diabetes. In: National Diabetes Data Group, editor. Diabetes in America. 2nd ed.Washington, DC: National Institutes of Health; 1995. p. 409-428.
10.
Apelqvist J, Larson J.What is the most effective way to reduce the incidence of amputation in the diabetic foot?Diabetes Metab Res Rev2000;16(Suppl 1):S75-S83.
11.
Rheinwald JG, Green H.Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell1975;6:331-344.
12.
Greenleaf G, Hansbrough JF.Current trends in the use of allograft skin for burn patients and reflections on the future of skin banking in the United Stares. J Burn Care Rehabil1995;15:428.
13.
Greenleaf G, Cooper ML, Hansbrough JF.Microbial contamination in allografted wound beds in patients with burns. J Burn Care Rehabil1991;12:442.
14.
Kealey GP.Disease transmission by means of allografts. J Burn Care Rehabil1997;18:10-11.
15.
Loots MAM, Lamme JR, Mekkes JR, et al.Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch Dermatol Res1999;291:93-99.
16.
Kolenik SA III, Lefell DJ.The use of cryopreserved human skin allografts in wound healing following Mohs surgery. Dermatol Surg1995;21:615-620.
Odyssey R.Multicenter experience with cultured epidermal autografts for treatment of burns. J Burn Care Rehabil1992;13:174-180.
19.
Limova M, Mauro T.Treatment of leg ulcers with cultured epithelial autografts: treatment protocol and five-year experience. Wounds1995;7:170-180.
20.
Teepe RGC, Koebrugge EJ, Ponec M, et al.Fresh versus cryopreserved allografts for the treatment of chronic skin ulcers. Br J Dermatol1990;122:81-89.
21.
Teepe RGC, Roseeuw DI, Hermans D, et al.Randomized trial comparing cryopreserved cultured epidermal allografts with hydrocolloid dressings in healing chronic venous ulcers. J Am Acad Dermatol1993;29:982-988.
22.
Phillips T.Cultured epidermal allografts: a temporary or permanent solution?Transplantation1991;51:937-941.
23.
Phillips T, Ghawan J, Leigh IM, et al.Cultured epidermal allografts: a study of differentiation and allograft survival. J Am Acad Dermatol1990;23:189-198.
24.
Phillips TJ, Kehinde O, Green H, et al.Treatment of skin ulcers with cultured epidermal allografts. J Am Acad Dermatol1989;21:191-199.
25.
Clark RAF. Basics of cutaneous wound repair. J Dermatol Surg Oncol1993;19:693-706.
26.
Burke JF, Yannas IV, Quinby WC, et al.Successful use of physiologically acceptable artificial skin in the treatment of extensive burn injury. Ann Surg1981;194:413-428.
27.
Mansbridge J, Liu K, Patch R, et al.Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. Tissue Eng1998;4(4):403-411.
28.
Landeen LK, Zeigler FC, Halberstadt C, et al.Characterization of a human dermal replacement. Wounds1992;5:167-175.
29.
McColgan M, Foster A, Edmonds M.Dermagraft in the treatment of diabetic foot ulcers. Diabetes Foot1998;1:75-78.
30.
Jiang WG, Harding KG.Enhancement of wound tissue expansion and angiogenesis by matrix-embedded fibroblasts (Dermagraft), a role of hepatocyte growth factor. Int J Mol Med1998;2:203-210.
31.
Perdue GF.Dermagraft-TC pivotal safety and efficacy study. J Burn Care Rehabil1996;18:S13-S14.
32.
Gentzkow GD, Iwasaki SD, Hershon KS, et al.Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care1996;19(4):350-354.
33.
Pollak RA, Edington H, Jensen JL, et al.The Dermagraft Diabetic Ulcer Study Group. A human dermal replacement for the treatment of diabetic foot ulcers. Wounds1997;9:175-178.
34.
Naughton G, Mansbridge J, Gentzkow G.A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs1997;21(11):1203-1210.
35.
Gentzkow GD, Pollak RA, Kroeker RO, et al.Implantation of a living human dermal replacement to heal diabetic foot ulcers. Presented at the 58th American Diabetes Association Scientific Sessions, Chicago, IL, June 13-16, 1998.
36.
Bowering CK.The use of Dermagraft in the treatment of diabetic foot ulcers. J Cutan Med Surg1998;3(Suppl 1):S1-S29-S32.
37.
Schwartz S.A new composite cultured skin product for treatment of burns and other deep dermal injury. Presented at the Bioengineering of Skin Substitute Conference, Boston, MA, September 19, 1997.
38.
Sabolinski ML, Alvarez O, Auletta M, et al.Cultured skin as a “smart material” for healing wounds: experience in venous ulcers. Biomaterials1996;17:311-320.
39.
Falanga V, Margolis D, Alverez O, et al.Healing of venous ulcer and lack of clinical rejection with an allogenic cultured human skin equivalent. Arch Dermatol1998;134:293-300.
40.
Falanga V, Sabolinski M.A bilayered living skin construct (Apligraf®) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen1999;7:201-207.
41.
Pham HT, Rosenblum BI, Lyons TE, et al.Evaluation of Graftskin (Apligraf®), a human skin equivalent, for the treatment of diabetic foot ulcers in a prospective, randomized, clinical trial. Wounds1999;11:79-86.
42.
Veves A, Falanga V, Armstrong DG, et al.for the Apligraf Diabetic Foot Ulcer Study Group. Graftskin, a human skin equivalent, is effective in the management of the non-infected neuropathic diabetic foot ulcers: a prospective, randomized, multicenter clinical trial. Diabetes Care2001;24:290-295.
43.
Falabella AF, Schachner LA, Valencia IC, et al.The use of tissue-engineering skin (Apligraf®) to treat a newborn with epidermolysis bullosa. Arch Dermatol1999;135(10):1219-1222.
44.
Eaglstein WH, Iriondo M, Laszlo K.A composite skin substitute (Graftskin) for surgical wounds. A clinical experience. Dermatol Surg1995;21(10):839-843.
45.
Eaglstein WH, Alverez OM, Auletta M, et al.Acute excisional wounds treated with a tissue-engineering skin (Apligraf®). Dermatol Surg1999;25(3):195-201.
46.
Kirsner RS.The use of Apligraf® in acute wounds. J Dermatol1998;25(12):805-811.
47.
Schonfeld WH, Villa KF, Fastenau JM.An economic assessment of Apligraf® (Graftskin) for the treatment of hard-to-heal venous leg ulcers. Wound Repair Regen2000;8(4):251-257.
48.
Allenet B, Paree F, Lebrun T, et al.Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes Metab2000;26(2):125-132.
